Sergančiųjų eksudacine amžine geltonosios dėmės degeneracija regėjimo aštrumo, akispūdžio ir centrinės tinklainės dalies storio pokyčiai dvejus metus gydant angiogenezės inhibitorių injekcijomis į stiklakūnį.

Aim of the study: To evaluate the changes in visual acuity, intraocular pressure and central retinal thickness in patients with exudative age-related macular degeneration within two years of treatment with intravitreal vascular endothelial growth factor inhibitors injections. Objectives: 1. To determine the mean of intravitreal vascular endothelial growth factor (VEGF) inhibitors injections for one patient with exudative age-related macular degeneration (AMD) over two year period and divide into groups according to the used preparation, the number of injections, type of choroidal neovascularization (CNV) established by optical coherence tomography (OCT). 2. To evaluate visual acuity, intraocular pressure and central retinal thickness (CRT) established by OCT before treatment with intravitreal VEGF inhibitors injections. 3. To evaluate visual acuity, intraocular pressure and CRT established by OCT after treatment with intravitreal VEGF inhibitors injections. 4. To compare visual acuity, intraocular pressure and CRT established by OCT between for treatment used preparation groups, number of intravitreal injections groups, types of CNV. Material and methods: A retrospective study was carried out to analyze the patiens with exudative AMD, who visited Department of Ophthalmology, the Hospital of LSMU Kauno klinikos in 2010 – 2016, ophthalmologic data and CRT measured using OCT. Results: The study group consisted of 132 patients with exudative AMD: 39 men (29,5 pct.) and 93 women (70,5 pct.). The number of examined eyes – 146. BCVA before treatment was 0,33 ± 0,21, after treatment – 0,31 ± 0,24. Intraocular pressure before treatment was 15,53 ± 2,44 mmHg, after treatment – 15,12 ± 2,38 mmHg. The mean of CRT measured by automatic measurements before treatment was 318,56 ± 132,89 µm, after treatment – 184,99 ± 85,18 µm. The mean of CRT measured by interactive measurements before treatment was 340,32 ± 140,26 μm, after treatment – 196,95 ± 101,47 μm. Conclusions: BCVA significantly decreased to half of subjects. Intraocular pressure significantly decreased to one third of subjects. CRT significantly decreased to more than three-quarters of subjects. BCVA results was better in subjects who had 10 – 22 injections than 1 – 6 within two years. BCVA was lower before treatment in the minimal classical CNV case than occult. CRT was higher before and after treatment in the minimal classical CNV case than occult